Sinopharm Vaccine Gets WHO Backing, Facilitating Broader Use
(Bloomberg) -- China's Sinopharm Group Co. won World Health Organization backing for its Covid-19 vaccine, paving the way for a wider rollout of the shot in countries scrambling for immunizations.
The WHO listed the vaccine for emergency use, Director General Tedros Adhanom Ghebreyesus said in a tweet on Friday. It's recommended for adults age 18 and over.
WHO's imprimatur for the state-owned pharmaceutical company's shot adds another option for Covax, a program supported by WHO and other global health groups that's aimed at ensuring every country has access to vaccinations. It joins a small supply of immunizations from Pfizer Inc. and its partner BioNTech SE, AstraZeneca Plc and Johnson & Johnson that are available especially to poor nations that have been shut out as wealthy countries wrapped up most of the existing vaccine supply.
The timing of the authorization is critical since India, the largest vaccine manufacturer, dramatically curtailed deliveries of the AstraZeneca shot it was providing to Covax. India is currently battling the largest outbreak in the world and the immunizations made there are being used locally.
Read More: The World Turns to China for Vaccines After India, U.S. Stumble
“The addition of this vaccine has the potential to rapidly accelerate Covid-19 vaccine access,” Mariangela Simao, WHO assistant-director general for access to health products, said in a statement.
The WHO's green light also bestows global legitimacy on the shot, and is especially influential in developing countries that lack their own regulatory bodies and rely on the international health organization's advice for which shots are safe. Sinopharm's shot is already being used in countries from Peru to Serbia, but no developed western country has approved it yet.
“It helps a lot to have an independent body review the data,” said Rupali Limaye, director of behavioral and implementation science at the International Vaccine Access Center at Johns Hopkins School of Public Health. “It will boost confidence, but use of the vaccines will still require a lot of persuasion at the public level.”
Performance Questions
The WHO nod could also pave the way for countries to allow in travelers who have received Chinese shots, even if the vaccine is not approved for use locally. Ahead of a planned reopening to vaccinated tourists this summer, the European Union has said that member countries can consider opening to people who have shots cleared by the WHO.
Despite the WHO backing, there are questions on how the Chinese vaccines, while protecting individuals from developing severe Covid-19, might help stop the virus from transmitting and infecting more people. The Sinopharm vaccine accounts for roughly 60% of doses administered in Seychelles, which has vaccinated more of its population than any other nation in the world but has still had to reinstate some virus-related curbs as cases surge. The shot's efficacy for preventing symptomatic and hospitalized disease was estimated to be 79% in all age groups combined, the WHO said.
World's Most-Vaccinated Nation Activates Curbs as Cases Rise
The vaccine contains inactive forms of the Sars-CoV-2 virus, which are injected to stimulate an immune response against the pathogen. The shot has been widely used in China since the middle of 2020. It has been sold or donated to nearly 60 countries and regions ranging from Hungary in the European Union to Egypt and Somalia in Africa since the start of this year.
The WHO is close to making a decision on another Chinese vaccine, this one from Sinovac Biotech Ltd., while Tianjin-based CanSino Biologics Inc. has started to submit data about its immunization to the health agency on a rolling basis.
©2021 Bloomberg L.P.
With assistance from Bloomberg
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.